CommercialCoverageMedium impact
Molecular Testing in the Management of Pulmonary Nodules
Blue Cross & Blue Shield of Mississippi·MS · Pulmonology, Oncology, Radiology +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi considers all molecular testing for pulmonary nodules investigational and non-covered, including plasma-based proteomic screening (Nodify XL2, Nodify CDT, REVEAL) and gene expression profiling (Percepta). This policy remains unchanged from previous versions but is being highlighted as a fresh policy update.
Action Required
Immediately: Billing team must verify that molecular testing for pulmonary nodules (Nodify XL2, Nodify CDT, REVEAL, Percepta Genomic Sequencing Classifier) is not being billed to BCBS Mississippi as these are considered investigational and will be denied. Review current claims and update denial management processes for these tests. Notify pulmonology providers that these tests are non-covered services requiring patient financial responsibility discussions.